Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine

A tetravalent dengue vaccine (CYD-TDV) has recently been approved in 12 countries in southeast Asia and Latin America for individuals aged 9–45 years or 9–60 years (age indication approvals vary by country) living in endemic areas. Data on utilization of medical and nonmedical resources as well as t...

Descripción completa

Detalles Bibliográficos
Autores principales: El Fezzazi, Hanna, Branchu, Marie, Carrasquilla, Gabriel, Pitisuttithum, Punnee, Perroud, Ana Paula, Frago, Carina, Coudeville, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805027/
https://www.ncbi.nlm.nih.gov/pubmed/29141713
http://dx.doi.org/10.4269/ajtmh.16-0952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805027/
https://www.ncbi.nlm.nih.gov/pubmed/29141713
http://dx.doi.org/10.4269/ajtmh.16-0952

Ejemplares similares